226 related articles for article (PubMed ID: 12673705)
1. Overview of bladder cancer trials in the European Organization for Research and Treatment.
de Wit R;
Cancer; 2003 Apr; 97(8 Suppl):2120-6. PubMed ID: 12673705
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel in the treatment of advanced urothelial cancer.
Bajorin DF
Oncology (Williston Park); 2000 Jan; 14(1):43-52, 57; discussion 58, 61-2. PubMed ID: 10680149
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y
Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
7. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
8. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
9. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
10. Review and outlook for the role of paclitaxel in urothelial carcinoma.
Vaughn DJ
Semin Oncol; 1999 Feb; 26(1 Suppl 2):117-22. PubMed ID: 10190793
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
Lehmann J; Retz M; Stöckle M
World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
[TBL] [Abstract][Full Text] [Related]
12. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
13. The role of ifosfamide in the treatment of testicular and urothelial malignancies.
Roth BJ
Semin Oncol; 1996 Jun; 23(3 Suppl 7):19-27. PubMed ID: 8711497
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
18. Overview of bladder cancer trials in the Cancer and Leukemia Group B.
Small EJ; Halabi S; Dalbagni G; Pruthi R; Phillips G; Edelman M; Bajorin D;
Cancer; 2003 Apr; 97(8 Suppl):2090-8. PubMed ID: 12673701
[TBL] [Abstract][Full Text] [Related]
19. Systemic chemotherapy options for metastatic bladder cancer.
Siefker-Radtke A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):877-85. PubMed ID: 16761931
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
Sternberg CN; de Mulder PH; Schornagel JH; Théodore C; Fossa SD; van Oosterom AT; Witjes F; Spina M; van Groeningen CJ; de Balincourt C; Collette L;
J Clin Oncol; 2001 May; 19(10):2638-46. PubMed ID: 11352955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
